SLC5A2 and pneumonia: Several observational studies have specifically examined infections such as pneumonia and sepsis, which have not been comprehensively evaluated in RCTs, and some suggest that SGLT2 inhibitors may reduce the risk of these infections compared to other glucose-lowering medications [15, 16].